Refining Breast Cancer Classification by Multiplexed Imaging

Breast cancer progression can vary significantly between patients. Even within the same tumor, different areas may be composed of different types of cells and characterized by different tumor structures. This heterogeneity makes it challenging to ascertain the severity of a tumor and assess its molecular subtype, thereby affecting the precision of diagnosis and the choice of the most effective treatment approach. More detailed characterization of a breast cancer tissue could help improve a treatment's chances of success and may decrease the risk of relapse.

The research group headed by Bernd Bodenmiller, professor of quantitative biology at UZH, has been able to refine the pathological classification of breast cancer using imaging mass cytometry. This method enables scientists to simultaneously visualize and analyze multiple biomarkers to generate information-rich digital images of tissue sections. In their study, the researchers quantified 35 protein biomarkers in breast cancer patients. "This created an unprecedented view of a tumor's cellular landscape and the surrounding tissue, which enabled us to determine whether more complex biomarkers exist for clinical outcome," explains Jana Fischer, co-first author of the study.

The team of researchers analyzed hundreds of tissue sections from 350 breast cancer patients and categorized the many cell components and how they are organized in cellular communities and form tumor tissues. "Four categories of breast cancer are routinely classified in the clinic, but our new analysis allows us to go further and identify multiple detailed subcategories of breast cancer. The danger from these diverse tumors can be very different, and each type could respond to therapy in its own way," explains co-first author Hartland Jackson.

This finding has the potential to change clinical practice. The new subgroups of breast cancer patients vary in their molecular profiles. Bernd Bodenmiller and his research team are now working on finding out which drugs are best able to combat tumor cells with a specific molecular profile. "By improving our ability to describe cellular features and categories as well as our ability to precisely identify patients that have high or low risk breast cancer, we're opening up new possibilities for precision medicine," says Bodenmiller.

Hartland W Jackson, Jana R Fischer, Vito RT Zanotelli, H Raza Ali, Robert Mechera, Savas D Soysal, Holger Moch, Simone Muenst, Zsuzsanna Varga, Walter P Weber, Bernd Bodenmiller.
The single-cell pathology landscape of breast cancer.
Nature, 2020. doi: 10.1038/s41586-019-1876-x.

Most Popular Now

MEDICA 2024 + COMPAMED 2024: Adapted Hal…

11 - 14 November 2024, Düsseldorf, Germany. The final preparations for MEDICA 2024 and COMPAMED 2024 in Düsseldorf have begun. A total of more than 5,500 exhibitors from approximately 70 countries...

AI does Not Necessarily Lead to more Eff…

The use of artificial intelligence (AI) in hospitals and patient care is steadily increasing. Especially in specialist areas with a high proportion of imaging, such as radiology, AI has long...

Commission Joins Forces with Venture Cap…

The Commission has launched a Trusted Investors Network bringing together a group of investors ready to co-invest in innovative deep-tech companies in Europe together with the EU. The Union's investment...

Why the NHS is Seeking to Make Media Ser…

Opinion Article by Dean Moody, Healthcare Services Director, Airwave Healthcare. Tim Kelsey and Martha Lane Fox called for WiFi to be made available free of charge throughout the NHS back in...

An AI-Powered Pipeline for Personalized …

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells and harnesses...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

AI could Transform How Hospitals Produce…

A pilot study led by researchers at University of California San Diego School of Medicine found that advanced artificial intelligence (AI) could potentially lead to easier, faster and more efficient...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...